Peter Theil, a former Genentech executive, has joined UCB SA as vice president and head of non-clinical development for new medicines. He will be based in Braine, Belgium and report to Ismail Kola, executive vice president, UCB and president of UCB NewMedicines. Mr Theil was formerly head of early development, pharmacokinetic and pharmacodynamic sciences at Genentech Inc, which is now part of the Roche Group. UCB announced the appointment on 25 November 2011.
Copyright 2012 Evernow Publishing Ltd